Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 20;27(1):17.
doi: 10.1186/s12575-025-00274-5.

Heterogeneity and efficacy of immunotherapy in multiple cancer: insights from a meta-analysis

Weidong Wu #  1   2 , Bin Liu #  3 , Qing Zhang #  4 , Xiaojuan Zhang  5 , Pengya Feng  6   7 , Yongliang Jia  8 , Xia Xue  9
Affiliations

Heterogeneity and efficacy of immunotherapy in multiple cancer: insights from a meta-analysis

Weidong Wu et al. Biol Proced Online. .

Abstract

Background: Immunotherapy has been recognized as a significant advancement in cancer treatment by promoting the body's immune system to identify and eliminate cancer cells more effectively. Unlike conventional therapies, immunotherapy can enhance the natural capabilities of human immune system. Chimeric Antigen Receptor T-cell (CAR-T) therapy involves genetical-modified T-cells from patients to better catch and attack cancer cells. Up to date, CAR-T therapy has shown particular promise in treating certain types of leukemia and lymphoma, highlighting the transformative potential of immunotherapy.

Results: Literature data search using PubMed, CNKI, and Wanfang were searched to collect eligible studies up to January 2025. The primary outcomes of complete response rate (CRR), objective response rate (ORR), dead rate (DR), and other adverse reactions were evaluated. Secondary outcomes (CRR, ORR, and DR) of subgroup analysis from different cancer types, origins, and outcomes for survival rate were analyzed for our final results. A total of 649 studies were initially identified through database searching. After removing duplicates and non-clinical cancer studies, 32 eligible studies were included in this work. The pooled data included 819 patients for objective response rate (ORR), 843 patients for complete response rate (CRR), and 868 patients for dead event. In the included studies, 24 reported ORR data, revealing an objective response rate of 84.86% (695/819) with little heterogeneity (OR: 0.87, 95% CI 0.80-0.91, P = < 0.01, I2 = 61%); 24 studies showed a CRR of 65.30% (491/843) with significant heterogeneity (OR: 0.58, 95% CI: 0.43-0.72, P < 0.01, I2 = 84%); 27 studies showed a mortality rate of 23.73% (206/868) with significant heterogeneity (OR: 0.19, 95% CI: 0.11-0.32, P < 0.01, I2 = 77%). Subgroup analysis based on cancer type revealed that ORR was higher in multiple myeloma (86.77%, 400/461) compared with leukemia (84.92%, 259/305) and lymphoma (67.92%, 36/53). In parallel, heterogeneity observed based on case origins suggested that Chinese cases showed significantly higher ORR, CRR, and survival rates compared with American ones.

Conclusions: This meta-analysis provides valuable insights into the potential of immunotherapy, particularly CAR-T, in cancer treatment. Findings showed the different efficacy and safety of immunotherapy in treating multiple cancers, with various objective response rates. Continued studies from more trials with different populations are needed to optimize their efficacy in further cancer treatment and precision medicine.

Keywords: Clinical outcomes; Different population; Hematological malignancies; Response rate.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This article does not cover animal or human testing. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flow diagram of the literature search and database selection
Fig. 2
Fig. 2
Primary outcomes of immunotherapy, which includes ORR, CRR, Dead number. a objective response rate (ORR). b Complete response rate (CRR). c Dead event present. a: anti-CD19 scFV/4- 1BB/CD3-ζ/IL4 shRNA and anti-BCMA scFV/CD3-ζ/CD28/OX40. b: anti-BCMA scFV/4- 1BB/CD3-ζ and anti-CD19 scFV/4- 1BB/CD3-ζ
Fig. 3
Fig. 3
Secondary outcomes of immunotherapy for various cancer. a Objective response rate (ORR). b Complete response rate (CRR). c Dead event present. a: anti-CD19 scFV/4- 1BB/CD3-ζ/IL4 shRNA and anti-BCMA scFV/CD3-ζ/CD28/OX40. b: anti-BCMA scFV/4- 1BB/CD3-ζ and anti-CD19 scFV/4- 1BB/CD3-ζ
Fig. 4
Fig. 4
Secondary outcomes of immunotherapy for cancer (American vs China). a Objective response rate (ORR). b Complete response rate (CRR). c Dead event present. a: anti-CD19 scFV/4- 1BB/CD3-ζ/IL4 shRNA and anti-BCMA scFV/CD3-ζ/CD28/OX40. b: anti-BCMA scFV/4- 1BB/CD3-ζ and anti-CD19 scFV/4- 1BB/CD3-ζ
Fig. 5
Fig. 5
The survival rate analysis based on different subgroup analysis. a Multiple cancer type subgroup. b Different population subgroup
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Bao Y. Study on the efficacy and safety of BCMA-targeted CAR-T in the treatment of relapsed/refractory multiple myeloma. Beijing: Tongfang Knowledge Network (Beijing) Technology Co., Ltd.; 2023. 10.27438/d.cnki.gyadu.2022.000460.
    1. Bezeljak U. Cancer gene therapy goes viral: viral vector platforms come of age. Radiol Oncol. 2022;56(1):1–13. 10.2478/raon-2022-0002. - PMC - PubMed
    1. Blumenschein GR, Devarakonda S, Johnson M, Moreno V, Gainor J, Edelman MJ, Heymach JV, Govindan R, Bachier C, Doger DSB, Matthew JF, Olszanski AJ, Vincent KL, Hyland N, Navenot JM, Fayngerts S, Wolchinsky Z, Broad R, Batrakou D, Pentony MM, Sanderson JP, Gerry A, Marks D, Bai J, Holdich T, Norry E, Fracasso PM. Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGEA10+ advanced non-small cell lung cancer. J ImmunoTherap Cancer. 2022;10(1):e003581. 10.1136/jitc-2021-003581. - PMC - PubMed
    1. Brudno JN, Natrakul DA, Karrs J, Patel N, Maass-Moreno R, Ahlman MA, Mikkilineni L, Mann J, Stroncek DF, Highfill SL, Fromm GC, Patel R, Pittaluga S, Kochenderfer JN. Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial. Blood Adv. 2024;8(3):802–14. 10.1182/bloodadvances.2023011470. - PMC - PubMed
    1. Chambers D, Rodgers M, Woolacott N. Not only randomized controlled trials, but also case series should be considered in systematic reviews of rapidly developing technologies. J Clin Epidemiol. 2009;62(12):1253-1260 e1254. 10.1016/j.jclinepi.2008.12.010. - PubMed

LinkOut - more resources